Single-Chain Fragment Variable Targeting KRAS G12V CAR T-Cell Therapy
Summary
USPTO published patent application US20260108609A1 on April 23, 2026, filed May 31, 2024, for a single-chain fragment variable (scFv) targeting KRAS G12V and a chimeric antigen receptor (CAR). The invention modifies a T cell receptor to recognize KRAS G12V mutant polypeptides presented by HLA-A*02:01, retaining the extracellular signaling domain linked to a CD3ζ-derived intracellular signaling domain for potential tumor treatment applications including CAR-T and NK cell therapy.
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108609A1 for a single-chain fragment variable (scFv) targeting the KRAS G12V mutation and a corresponding chimeric antigen receptor (CAR). The application describes modifying a T cell receptor to specifically recognize KRAS G12V mutant polypeptides presented by HLA-A*02:01, retaining the extracellular signaling domain and linking it to a CD3ζ-derived intracellular signaling domain. The inventors, Zhenyu XU and Huimin SHAO, disclose applications in CAR-T and NK cell therapies for potential cancer treatment.
Affected parties in the biotechnology, pharmaceutical, and oncology sectors should monitor this published application to assess potential freedom-to-operate considerations and competitive landscape impacts related to KRAS G12V-targeted cell therapies.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SINGLE-CHAIN FRAGMENT VARIABLE TARGETING KRAS G12V, CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF
Application US20260108609A1 Kind: A1 Apr 23, 2026
Inventors
Zhenyu XU, Huimin SHAO
Abstract
Disclosed are a single-chain fragment variable (scFv) targeting KRAS G12V, a chimeric antigen receptor (CAR), and a use thereof. Based on the KRAS G12V target, a T cell receptor (TCR) is modified. An extracellular signaling domain of the TCR for recognizing a tumor-specific antigen (TSA) is retained and linked in series to an extracellular spacer, a transmembrane domain, and a CD3ζ-derived intracellular signaling domain in the conventional CAR structure, such that the modified CAR can specifically recognize a KRAS G12V mutant polypeptide presented by HLA-A*02:01. Moreover, based on the advantages of CAR-T cell/NK cell therapy, potential new tumor treatment options are explored to lay a foundation for clinical trials.
CPC Classifications
A61K 40/4253 A61K 40/11 A61K 40/31 A61P 35/00 C07K 14/7051 C07K 16/40 C07K 2317/569
Filing Date
2024-05-31
Application No.
19132969
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.